Dronabinol
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $340,508 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $340,508 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1, Proof-of-Concept, Single-Dose, Open-Label, Two-Treatment, Crossover, Comparative Bioavailability Study of Dronabinol Inhalation Aerosol (0.35 mg) and Marinol Capsules (5 mg) in Healthy Adult Volunteers under Fasted Conditions | INSYS Therapeutics Inc | $340,508 | 0 |
Top Doctors Receiving Payments for Dronabinol
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Austin, TX | $340,508 | 4 |
Manufacturing Companies
- INSYS Therapeutics Inc $340,508
Product Information
- Type Drug
- Total Payments $340,508
- Total Doctors 0
- Transactions 4
About Dronabinol
Dronabinol is a drug associated with $340,508 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is INSYS Therapeutics Inc.
Payment data is available from 2018 to 2018. In 2018, $340,508 was paid across 4 transactions to 0 doctors.
The most common payment nature for Dronabinol is "Unspecified" ($340,508, 100.0% of total).
Dronabinol is associated with 1 research study, including "A Phase 1, Proof-of-Concept, Single-Dose, Open-Label, Two-Treatment, Crossover, Comparative Bioavailability Study of Dronabinol Inhalation Aerosol (0.35 mg) and Marinol Capsules (5 mg) in Healthy Adult Volunteers under Fasted Conditions" ($340,508).